Income Tax Disclosure: Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($) |
3 Months Ended | 9 Months Ended | |||
|---|---|---|---|---|---|
May 31, 2025 |
May 31, 2024 |
May 31, 2025 |
May 31, 2024 |
Aug. 31, 2024 |
|
| Details | |||||
| Income tax expense (benefit) at statutory rate | $ 886,886 | $ 805,466 | |||
| Change in valuation allowance for loss carryforward | $ 17,098 | 17,098 | $ 15,313 | ||
| Income tax expense (benefit) | $ 0 | $ 0 | $ 0 | $ 0 | |
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|